After TG Therapeutics announced that umbralisib received FDA Breakthrough Therapy Designation in the treatment of adult marginal zone lymphoma patients, H.C. Wainwright analyst Edward White noted that he estimates umbralisib will be launched in the non-Hodgkin’s lymphoma indication in 2021. White, who continues to view U2 therapy as a potential base for triplet or quad combination therapy in NHL patients, keeps a Buy rating and $20 price target on TG Therapeutics shares.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.